Clinical Research Directory
Browse clinical research sites, groups, and studies.
CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr
Sponsor: European Institute of Oncology
Summary
This is a prospective observational study. The study will proceed with the enrollment of 60 patients in 2 years. he aim of the present study is to evaluate effectiveness of ultra-hypofractionated (UH) CyberKnife Stereotactic Body Radiation Therapy treatment on the whole prostate gland plus Simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL(s) in intermediate-unfavourable to high-risk Prostate Cancer (PCa) patients.
Official title: CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr With Dose-escalation to the Dominant Intraprostatic Lesion: is the Juice Worth the Squeeze? The PRO-SPEED Trial
Key Details
Gender
MALE
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-02-20
Completion Date
2029-12-31
Last Updated
2025-08-28
Healthy Volunteers
No
Conditions
Interventions
CyberKnife ultra-hypofractionated SBRT
CyberKnife ultra-hypofractionated SBRT for localized Prostate cancer with dose-escalation to the dominant intraprostatic lesion
Locations (1)
European Institute of Oncology
Milan, Italy